Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2020 01:00 ET | Source: Basilea Pharmaceutica AG

Basilea gibt einen Wandelpreis von CHF 62.50 für ihre Neue Anleihe und die Annahme angedienter Wandelobligationen mit einem Gesamtnennbetrag von rund CHF 47 Millionen bekannt

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Schweiz, 21. Juli 2020 Basilea Pharmaceutica AG („Basilea“ oder...
July 21, 2020 01:00 ET | Source: Basilea Pharmaceutica AG

Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Switzerland, July 21, 2020 Basilea Pharmaceutica Ltd....
July 20, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea gibt Abschluss der Patientenrekrutierung für die erste Kohorte der Phase-2-Studie FIDES-01 mit Derazantinib bei Gallengangkrebs (iCCA) bekannt

Basel, 20. Juli 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Abschluss der Patientenrekrutierung für die erste Kohorte der Phase-2-Zulassungsstudie FIDES-01 bekannt. In der Studie...
July 20, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)

Basel, Switzerland, July 20, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the completion of patient enrolment into the first cohort of the phase 2 registrational study, FIDES-01,...
July 17, 2020 13:08 ET | Source: Basilea Pharmaceutica AG

Basilea führt das Rückkaufangebot und die Ausgabe Neuer Anleihen fort

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Schweiz, 17. Juli 2020 Nach dem Ende der Angebotsfrist am 16....
July 17, 2020 13:08 ET | Source: Basilea Pharmaceutica AG

Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Switzerland, July 17, 2020 Following the closing of the tender offer...
July 17, 2020 01:00 ET | Source: Basilea Pharmaceutica AG

Obligationen der Basilea mit einem Gesamtnennbetrag von ungefähr CHF 47 Millionen angedient

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Schweiz, 17. Juli 2020 Nach dem Ende der Angebotsfrist am 16. Juli...
July 17, 2020 01:00 ET | Source: Basilea Pharmaceutica AG

Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Switzerland, July 17, 2020 Following the closing of the tender offer...
July 15, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea gibt Markteinführung des Antimykotikums Cresemba® (Isavuconazol) in Taiwan bekannt, wodurch die zweite Meilensteinzahlung für den asiatisch-pazifischen Raum ausgelöst wird

Basel, 15. Juli 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Lizenzpartner Pfizer Inc. (NYSE: PFE, “Pfizer”) das Antimykotikum Cresemba® (Isavuconazol) in Taiwan lanciert...
July 15, 2020 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific

Basel, Switzerland, July 15, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license partner, Pfizer Inc. (NYSE: PFE, “Pfizer”), has launched the antifungal Cresemba®...